OUR PRESS RELEASES AND NEWS UPDATES
These press releases and news updates are intended for media and investors only
Showing results for
-
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
24 Mar 2022ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period -
ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
04 Jul 2020High levels of engagement between healthcare providers and people living with HIV are associated with better health outcomes -
March
14 Mar 2019
These press releases and news updates are intended for media and investors only
-
Our response to the situation in Ukraine
22 May 2023 -
ViiV Healthcare PatientView 2022-2023 survey results
28 Apr 2023ViiV Healthcare is ranked number one for the tenth consecutive year in PatientView’s Corporate Reputation of Pharma – from the Patient Perspective 2022 - 2023 survey -
Update on ViiV’s response to COVID-19
21 Apr 2020 -
COVID-19 Guidance to Investigators
27 Mar 2020 -
ViiV’s position on COVID-19 outbreak
17 Mar 2020
Media contacts
Media contact details for our global headquarters and USA. For press contacts in our local operating companies please visit our country websites.
In you have a media query please use our Contact our team form here.
Global Press Office
Rachel Jaikaran
Head of Global Communications ViiV Healthcare
Tel: +44 7909 00240
US Press Office
Audrey Abernathy
Head of ViiV US External Affairs & Communications
Tel: +1 919 605 4521
NP-GBL-HVX-COCO-220024 November 2021.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
